Mitomycin as adjunct chemotherapy with trabeculectomy in congenital and developmental glaucomas

Purpose: To report on sixty-eight patients (98 eyes) who were trabeculectomized with the use of mitomycin C as adjunctive therapy. Methods: Fifty-six patients (79 eyes) were followed for at least 6 months or had IOP of >21 mm HG or any complications that were considered end point for them. Forty-six were primary congenital glaucoma; one was Sturger Weber disease; five were Axenfeld-Rieger syndrome; two were Peters anomaly; one was congenital glaucoma associated with ectopia lentis and one aniridia. The mean age was 76.06 ± 81.56 months (range, 1 month to 30 years). Results: Fifty-three eyes (67.09%) were considered successful (IOP ≤ 21 mm Hg) with a mean follow-up of 17.30 ± 7.98 months (range, 6-44 months). From these, 47 eyes (59.49%) had IOP ≤ 16 mm Hg. Twenty-three eyes had IOP of >21 mm Hg (30.37%), one developed retinal detachment, (1.26%) two developed phthisis (2.53%), eight had flat anterior chamber (10.12%), two vitreous hemorrhage (2.53%), and four choroidal detachment (5.06%). Conclusions: Despite the number of complications, some of them very serious, the use of mitomycin seems to be a reasonable approach in these eyes with very poor surgical prognosis, otherwise candidates for setons.